Mein Warenkorb

SIRP alphaV8

SIRP alphaV8 Molekülinformation

Englischer NameSignal-regulatory protein alphaAnzahl der inverkehr gebrachten Arzneimittel2
Anzahl der klinischen Arzneimittel19Target-AliasSHPS-1,Macrophage fusion receptor,Brain Ig-like molecule with tyrosine-based activation motifs,MFR,Signal-regulatory protein alpha-1,Signal-regulatory protein alpha-2,CD172a,MyD-1 antigen,Sirp-alpha-3,MYD1,SIRPA,Signal Regulatory Protein Alpha,CD172 Antigen-Like Family Member A,Inhibitory Receptor SHPS-1,PTPNS1,SHPS1,SIRP,P84,Brain-Immunoglobulin-Like Molecule With Tyrosine-Based Activation Motifs,Protein Tyrosine Phosphatase, Non-Receptor Type Substrate 1,Tyrosine-Protein Phosphatase Non-Receptor Type Substrate 1,Tyrosine Phosphatase SHP Substrate 1,Signal-Regulatory Protein Alpha-3,Signal-Regulatory Protein Alpha,SHP Substrate 1,CD172a Antigen,Sirp-Alpha-1,Sirp-Alpha-2,MYD-1,Bit,SIRPalpha,SIRPalpha2
Höchste Forschungs- und EntwicklungsphaseApproved
Englischer NameSignal-regulatory protein alpha
Target-AliasSHPS-1,Macrophage fusion receptor,Brain Ig-like molecule with tyrosine-based activation motifs,MFR,Signal-regulatory protein alpha-1,Signal-regulatory protein alpha-2,CD172a,MyD-1 antigen,Sirp-alpha-3,MYD1,SIRPA,Signal Regulatory Protein Alpha,CD172 Antigen-Like Family Member A,Inhibitory Receptor SHPS-1,PTPNS1,SHPS1,SIRP,P84,Brain-Immunoglobulin-Like Molecule With Tyrosine-Based Activation Motifs,Protein Tyrosine Phosphatase, Non-Receptor Type Substrate 1,Tyrosine-Protein Phosphatase Non-Receptor Type Substrate 1,Tyrosine Phosphatase SHP Substrate 1,Signal-Regulatory Protein Alpha-3,Signal-Regulatory Protein Alpha,SHP Substrate 1,CD172a Antigen,Sirp-Alpha-1,Sirp-Alpha-2,MYD-1,Bit,SIRPalpha,SIRPalpha2
Anzahl der inverkehr gebrachten Arzneimittel2
Anzahl der klinischen Arzneimittel19
Höchste Forschungs- und EntwicklungsphaseApproved

SIRP alphaV8 Produktliste

  • Attribut

    Protein (2)

  • Produktbibliothek

    Online (2)

  • Spezies

    Human (2)

  • Etikett

    His Tag & Avi Tag (1)His Tag (1)

  • Marker

    Biotin-labeled (1)Unconjugated (1)

ProduktnummerSpeziesExpressionssystemProduktbeschreibungProteinstrukturReinheitEigenschaftenVorbestellen/Bestellen
SI8-H52H5
Human
HEK293
Human SIRP alphaV8 / CD172a Protein, His Tag (MALS verified)
In den Warenkorb legen
SI8-H82W6
Human
HEK293
Biotinylated Human SIRP alphaV8 / CD172a Protein, His,Avitag™
In den Warenkorb legen
Gesamtmenge2
  • 1

SIRP alphaV8 Molekülhintergrund

Tyrosine-protein phosphatase non-receptor type substrate 1 (SHPS1) is also known as CD172 antigen-like family member A (CD172a), Macrophage fusion receptor, MyD-1 antigen, Signal-regulatory protein alpha (SIRPA or SIRP alpha) or p84, is a member of the SIRP family, and also belongs to the immunoglobulin superfamily. SIRP alpha is Ubiquitous and highly expressed in brain. SIRPA / CD172a is immunoglobulin-like cell surface receptor for CD47 and acts as docking protein and induces translocation of PTPN6, PTPN11 and other binding partners from the cytosol to the plasma membrane. SIRPA / SHPS-1 supports adhesion of cerebellar neurons, neurite outgrowth and glial cell attachment and may play a key role in intracellular signaling during synaptogenesis and in synaptic function By similarity. SIRPA / MyD1 involved in the negative regulation of receptor tyrosine kinase-coupled cellular responses induced by cell adhesion, growth factors or insulin and mediates negative regulation of phagocytosis, mast cell activation and dendritic cell activation. CD47 binding prevents maturation of immature dendritic cells and inhibits cytokine production by mature dendritic cells.

SIRP alphaV8 Molekülalias

SHPS1,SIRPA,CD172A,BIT,MFR,MYD1,P84,PTPNS1

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
IpsoprubartELA-026Phase 3 ClinicalElectra Therapeutics IncLymphohistiocytosis, Hemophagocytic; Neoplasms
Details
LM-101LM-101Phase 2 ClinicalLaNova Medicines LtdHematologic Neoplasms; Leukemia; Neoplasms; Solid tumours
Details
HX-044HX044; HX-044Phase 2 ClinicalHanx Biopharmaceuticals Pty LtdLymphoma; Solid tumours
Details
BRB-002BRB-002Phase 2 ClinicalBitterroot Bio IncAtherosclerosis; Cardiovascular Diseases; Vasculitis
Details
BI-770371BI-770371Phase 2 ClinicalOse ImmunotherapeuticsCarcinoma, Non-Small-Cell Lung; Liver Cirrhosis; Melanoma; Metabolic Dysfunction-Associated Steatotic Liver Disease; Solid tumours; Squamous Cell Carcinoma of Head and Neck
Details
IBC-0966IBC-0966Phase 2 ClinicalNeoplasms
Details
HX-009HX-009; HX009-II-02Phase 2 ClinicalWaterstone Hanxbio Pty LtdBile Duct Neoplasms; Biliary Tract Neoplasms; Liver Neoplasms; Lymphoma; Melanoma; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms
Details
BI-765063OSE-172; BI-765063; Effi-DEMPhase 1 ClinicalEffimuneCarcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Melanoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck
Details
ADU-1805ADU-1805Phase 1 ClinicalAduro Biotech IncCarcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Neoplasms; Solid tumours
Details
Q-1801Q-1801; Q 1801Phase 1 ClinicalQure Biotechnology (Shanghai) Co LtdSolid tumours
Details
Recombinant humanized IgG4 anti-SIRPα antibody(Daiichi Sankyo)DS-1103aPhase 1 ClinicalDaiichi Sankyo Co LtdBreast Neoplasms; Solid tumours
Details
JY-47JY47; JY-47Phase 1 ClinicalHangzhou Jiuyuan Gene Biomedical Co LtdLiver Cirrhosis; Metabolic Dysfunction-Associated Steatotic Liver Disease; Solid tumours
Details
BYON-4228BYON-4228Phase 1 ClinicalSanquin Blood Supply FoundationLymphoma; Solid tumours
Details
BSI-082BSI-082Phase 1 ClinicalBiosion IncHematologic Neoplasms; Neoplasm Metastasis; Solid tumours
Details
BR-105BR-105; BR105Phase 1 ClinicalHisun Biopharmaceutical Co Ltd, Zhejiang BioRay Biopharmaceuticals Co LtdLymphoma, Large B-Cell, Diffuse; Neoplasms
Details
[89Zr]Zr- BI-765063(Boehringer Ingelheim)Phase 1 ClinicalBoehringer Ingelheim CorpCarcinoma, Non-Small-Cell Lung; Melanoma; Squamous Cell Carcinoma of Head and Neck
Details
TQB-2928TQB-2928Phase 1 ClinicalJiangsu Chia Tai-Tianqing Pharmaceutical Co LtdCarcinoma, Non-Small-Cell Lung; Hematologic Neoplasms; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neoplasms; Osteosarcoma; Solid tumours
Details
BI-765080Phase 1 ClinicalC.H. Boehringer Sohn Ag & Co. Kg
Details
ES-004ES-004; ES 004-N4; ES 004-B4Phase 1 ClinicalElpiscience (Shanghai) Biopharma LtdNeoplasms; Solid tumours
Details

Inverkehr gebrachte Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaFrühestes MarkennameFrühestes GenehmigungslandFrüheste IndikationFrüheste GenehmigungsgesellschaftFrüheste GenehmigungsdatumIndikationenKlinische Studie
Relugolix/Estradiol/Norethindrone AcetateE2/NETAApprovedMyovant SciencesMYFEMBREE, RYEQOUnited StatesMenorrhagia; LeiomyomaSumitomo Pharma America Inc, Myovant Sciences2021-05-26Endometriosis; Leiomyoma; Menorrhagia; Pain; Uterine Neoplasms
Details
Elagolix/estradiol/norethindrone acetateApprovedAbbvie IncOriahnnUnited StatesMenorrhagiaAbbvie Inc2020-05-29Menorrhagia
Details
  • Molekülinformation
  • Produktliste
  • Inverkehr gebrachte Arzneimittelinformation
  • Klinische Arzneimittelinformation
Kontaktieren Sie uns